Tiagabine for acute affective episodes in bipolar disorder. by Vasudev, A, Macritchie, K, Rao, S, Geddes, J, Young, A

“…We contacted authors, other experts in the field and pharmaceutical companies for knowledge of suitable published or unpublished trials. …”

Comparative efficacy of pharmacological and non-pharmacological interventions for the acute treatment of adult outpatients with anorexia nervosa: study protocol for the systematic... by Wade, T, Treasure, J, Schmidt, U, Fairburn, C, Byrne, S, Zipfel, S, Cipriani, A

“…<br/><br/> Methods: Searches of electronic data bases will be supplemented with manual searches for published, unpublished and ongoing RCTs in international registries, and clinical trials registries of regulatory agencies and pharmaceutical companies. Two reviewers will independently extract the data and where possible we will access individual data in order to examine moderators of treatment. …”

Chemical Survey of Three Species of the Genus <i>Rauhia</i> Traub (Amaryllidaceae) by Luciana R. Tallini, Edison H. Osorio, Strahil Berkov, Laura Torras-Claveria, María L. Rodríguez-Escobar, Francesc Viladomat, Alan W. Meerow, Jaume Bastida

“…Obtaining this active pharmaceutical ingredient, still sourced on an industrial scale from the Amaryllidaceae species, is a challenge for pharmaceutical companies due to its low natural yield and the high cost of its synthesis. …”
Get full text

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system by Huyen Le, Ru Chen, Stephen Harris, Hong Fang, Beverly Lyn-Cook, Huixiao Hong, Weigong Ge, Paul Rogers, Weida Tong, Wen Zou

“…However, the drug names in the adverse event (AE) reports from FAERS were heterogeneous due to a lack of uniformity of information submitted mandatorily by pharmaceutical companies and voluntarily by patients, healthcare professionals, and the public. …”
Get full text

Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide by Matthew Ventresca, Holger J. Schünemann, Fergus Macbeth, Mike Clarke, Lehana Thabane, Gareth Griffiths, Simon Noble, David Garcia, Maura Marcucci, Alfonso Iorio, Qi Zhou, Mark Crowther, Elie A. Akl, Gary H. Lyman, Viktoria Gloy, Marcello DiNisio, Matthias Briel

“…We present short descriptions of these articles alongside overviews of IPD sharing policies and procedures of pharmaceutical companies which display certification of Principles for Responsible Clinical Trial Data Sharing via Pharmaceutical Research and Manufacturers of America or European Federation of Pharmaceutical Industries and Associations websites. …”
Get full text

Local causes of essential medicines shortages from the perspective of supply chain professionals in Saudi Arabia by Yazed AlRuthia, Nouf Mohammed Almutiri, Raghdah Musa Almutairi, Omar Almohammed, Hani Alhamdan, Sobhi Ali El-Haddad, Yousif Abdu Asiri

“…Furthermore, failure of pharmaceutical companies to inform SFDA of potential drug shortages, manufacturing issues, poor demand forecasting, unpredictable increase in demand, and low prices of essential drugs were also believed to be behind the observed interruptions in the supply of some essential medicines. …”
Get full text

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. by Shamila S Gunatilleke, Claudia M Calvet, Jonathan B Johnston, Chiung-Kuang Chen, Grigori Erenburg, Jiri Gut, Juan C Engel, Kenny K H Ang, Joseph Mulvaney, Steven Chen, Michelle R Arkin, James H McKerrow, Larissa M Podust

“…Lead compounds developed by pharmaceutical companies against these targets could also be explored for efficacy against T. cruzi.…”
Get full text

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines by Magdalena Bujar, Magdalena Bujar, Neil McAuslane, Stuart Walker, Stuart Walker, Sam Salek

“…This study aimed to further establish the measurement properties of the QoDoS by evaluating its reliability (internal consistency and test-retest reliability) and relevance in the target population.Methods: The study participants consisted of 55 individuals recruited from pharmaceutical companies, regulatory and HTA agencies. It was designed as a longitudinal study with participants assessed on two different occasions, at baseline (test 1) and then 7 days later (test 2). …”
Get full text

Supplementary protection of intellectual property rights for medicines by A.O. Kodynets, O.F. Doroshenko, I.P. Volynets, G.K. Dorozhko, V.O. Petrenko, V.V. Belitsky

“…Examples of patents for medicines owned by global pharmaceutical companies (Gilead, Bayer Intellectual Property Gmbh, etc.) that have ensured their commercial success and competitive advantages are examined. …”
Get full text

Hurdles and signposts on the road to virtual control groups—A case study illustrating the influence of anesthesia protocols on electrolyte levels in rats by A. Gurjanov, A. Kreuchwig, T. Steger-Hartmann, L. A. I. Vaas

“…Based on the data curation and sharing activities of the Innovative Medicine Initiatives project eTRANSAFE (enhancing TRANSlational SAFEty Assessment through Integrative Knowledge Management) the ViCoG working group was established with the objectives of i) collecting suitable historical control data sets from preclinical toxicity studies, ii) evaluating statistical methodologies for building adequate and regulatory acceptable VCGs from historical control data, and iii) sharing those control-group data across multiple pharmaceutical companies. During the qualification process of VCGs a particular focus was put on the identification of hidden confounders in the data sets, which might impair the adequate matching of VCGs with the CCG.Methods: During our analyses we identified such a hidden confounder, namely, the choice of the anesthetic procedure used in animal experiments before blood withdrawal. …”
Get full text

Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine by Giuseppe Novelli, Giuseppe Novelli, Giuseppe Novelli, Paola Spitalieri, Michela Murdocca, Eleonora Centanini, Federica Sangiuolo

“…Hence, in the context of drug discovery, Organoid Factories can offer biobanks of validated 3D organoid models that can be used in collaboration with pharmaceutical companies to speed up the drug screening process. …”
Get full text

Artificial Intelligence in Pharmaceuticals: Exploring Applications and Legal Challenges by fatemeh shaki, Mohamadsadegh Amilrkhanloo, Danial Jahani, Milad Chahrdori

“…This approach can aid regulatory authorities and pharmaceutical companies identify and address potential medication risks more effectively. …”
Get full text

Non-adherence to guideline recommendations for insulins: a qualitative study amongst primary care practitioners by M. Dankers, M. J. E. van den Berk-Bulsink, M. van Dalfsen-Slingerland, H.J.M.G. Nelissen-Vrancken, A. K. Mantel-Teeuwisse, L. van Dijk

“…The belief that guideline-recommended insulins were less effective, positive experience with other insulins and marketing from pharmaceutical companies were also identified as attitude-related barriers to prescribe guideline-recommended insulins. …”
Get full text

Biobanks in the low- and middle-income countries of the Arab Middle East region: challenges, ethical issues, and governance arrangements—a qualitative study involving biobank manag... by Ahmed Samir Abdelhafiz, Mamoun Ahram, Maha Emad Ibrahim, Alya Elgamri, Ehsan Gamel, Rania Labib, Henry Silverman

“…Five managers avoided partnerships with pharmaceutical companies due to concerns with unfavorable reactions from the community. …”
Get full text

Readability of information imprinted in patient information leaflets (PILs) in Saudi Arabia: The case of antihypertensive medications by Aljoharah M Algabbani, Shahad A Alzahrani, Salwa M Almomen, Radwan A Hafiz

“…The Arabic and English PILs were extracted from the Saudi Drugs Information System (SDI) and pharmaceutical companies' registration documents. The study used Flesch-Kincaid grade level to assess the readability of English and sentence length to assess the Arabic texts. …”
Get full text

Global survey of consumer organizations advocating for safer nicotine products by Tomasz Jerzyński, Jessica Harding, Gerry V. Stimson

“…None reported receiving funding from tobacco or pharmaceutical companies. All pointed to important achievements in the public debate about SNP and tobacco harm reduction. …”
Get full text

Comparative efficacy of pharmacological and non-pharmacological interventions for the acute treatment of adult outpatients with anorexia nervosa: study protocol for the systematic... by Tracey D. Wade, Janet Treasure, Ulrike Schmidt, Christopher G. Fairburn, Susan Byrne, Stephan Zipfel, Andrea Cipriani

“…Methods Searches of electronic data bases will be supplemented with manual searches for published, unpublished and ongoing RCTs in international registries, and clinical trials registries of regulatory agencies and pharmaceutical companies. Two reviewers will independently extract the data and where possible we will access individual data in order to examine moderators of treatment. …”
Get full text

Motivating antibiotic stewardship in Bangladesh: identifying audiences and target behaviours using the behaviour change wheel by Leanne E. Unicomb, Fosiul Alam Nizame, Mohammad Rofi Uddin, Papreen Nahar, Patricia J. Lucas, Nirnita Khisa, S. M. Salim Akter, Mohammad Aminul Islam, Mahbubur Rahman, Emily K. Rousham

“…Methods We used formative research to explore contextual drivers of antibiotic sales, purchase, consumption/use and promotion among four groups: 1) households, 2) drug shop staff, 3) registered physicians and 4) pharmaceutical companies/medical sales representatives. We used formative research findings and an intervention design workshop with stakeholders to select target behaviours, prioritise audiences and develop SBCC messages, in consultation with a creative agency, and through pilots and feedback. …”
Get full text

Need for the Development of Dialectical Thinking in Pharmaceutical Personnel to Improve Their Performance in the Pharmacovigilance System by A. E. Krasheninnikov, B. K. Romanov, R. S. Safiullin, N. V. Shestakov

“…Most respondents tend to exaggerate the role of executive authorities, medical organisations, and pharmaceutical companies in the pharmacovigilance system and underestimate the role of pharmacies and pharmacy staff (only 17.62% of the respondents assign this role to pharmacies), which may be the reason for failing to fulfil pharmacovigilance duties and passing the responsibility to other parties to the circulation of medicinal products.Conclusions: according to the consolidated results, pharmacy employees may not consider themselves to be leading implementers of legislative initiatives, causally related to the effectiveness of pharmacovigilance system as a whole. …”
Get full text

The endless frontier? The recent increase of R&D productivity in pharmaceuticals by Fabio Pammolli, Lorenzo Righetto, Sergio Abrignani, Luca Pani, Pier Giuseppe Pelicci, Emanuele Rabosio

“…Moreover, we show that biotechnology companies have reached levels of productivity in project development that are equivalent to those of large pharmaceutical companies. Conclusions Our study reports on the state of R&D productivity in the bio-pharmaceutical industry, finding several signals of an improving performance, with R&D projects becoming more targeted and novel in terms of indications and mechanisms of action.…”
Get full text